Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and ...

Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and profitability quietly improve. See our latest ...

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2026. [Operator Instructions] I would now like to turn the call over to David Clair, ...

Nov 5 (Reuters) - Biotech firm Bio-Techne (TECH.O), opens new tab on Wednesday missed Wall Street estimates for first-quarter revenue, hurt by subdued demand for its products, sending its shares down ...

Use of Non-GAAP Financial Measures: This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). We ...

Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2025-11-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...

Visualizes functional protein-protein interactions directly within fixed tissue at subcellular resolution Enables simultaneous detection of protein proximity, RNA, and proteins on the same tissue ...

Fintel reports that on October 14, 2025, TD Cowen maintained coverage of Bio-Techne (NasdaqGS:TECH) with a Buy recommendation. Analyst Price Forecast Suggests 12.98% Upside As of September 30, 2025, ...

Shares of Bio-Techne Corp. TECH slid 5.98% to $50.96 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.30% to 6,532.04 and ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...